As summarized in the WHO CNS5, the mutation-site genotypes of genes such as isocitrate dehydrogenase (IDH), tumor protein p53 (P53), and alpha thalassemia/mental retardation syndrome X-linked (ATRX) are important indicators for the classification of gliomas [13]. This evidence concerns the gene ATRX and central nervous system cancer.